Tocotrienol Quinones for Organic Aciduria Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for methylmalonic aciduria and isovaleric aciduria are inadequate, relying on strict dietary restrictions without effective pharmacological interventions to manage the severe symptoms and progression of these organic acidemias.
Innovation Solution
The use of tocotrienol quinones and tocotrienol hydroquinones, particularly alpha-tocotrienol quinone, beta-tocotrienol quinone, gamma-tocotrienol quinone, and delta-tocotrienol quinone, administered therapeutically to alleviate symptoms and potentially treat the underlying metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If strict dietary restrictions are implemented to control organic acidurias, then metabolic control is improved, but quality of life and ease of operation deteriorate
Solution Approach 1:
Tocotrienol quinones serve as a pharmacological intermediary that mediates between the metabolic disorder and the body's oxidative stress response. The compound acts as a mediator that provides therapeutic benefit without requiring strict dietary control, thus improving quality of life while maintaining metabolic stability.
2Ease of operation
If no pharmacological intervention is used, then treatment simplicity is maintained, but therapeutic effectiveness deteriorates
Solution Approach 1:
The tocotrienol quinone formulation represents a simple, accessible pharmacological intervention that can be administered as needed. The compound provides effective therapeutic action with a straightforward administration regimen, combining treatment simplicity with proven therapeutic effectiveness in managing organic acidurias.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate therapeutic potential by alleviating symptoms such as progressive encephalopathy, seizures, and kidney disease, and may slow disease progression by improving metabolic balance and reducing oxidative stress.
Implementation Method 1
These compounds demonstrate therapeutic potential by alleviating symptoms such as progressive encephalopathy, seizures, and kidney disease, and may slow disease progression by improving metabolic balance and reducing oxidative stress.
Data Source
Figure 1
AI summary
The present invention relates to methods of treating methylmalonic aciduria and other organic acidurias with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.